Cardax, Inc. Announces Sales Results for the Third Quarter and Nine Months of 2018
November 13, 2018 at 05:00 pm EST
Share
Cardax, Inc. announces sales results for the third quarter and nine months of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased 102% from $272,049 in second quarter of 2018 to $549,540 in third quarter of 2018. Third quarter of 2018 revenues also increased 71% from $321,861 in third quarter of 2017.
Revenues for the nine-months ended September 30, 2018 grew 129% to $1,134,899 from $496,088 for the same nine month period in 2017.
Cardax, Inc. is a consumer health company focused on marketing ZanthoSyn, an astaxanthin dietary supplement for inflammatory health. It seeks to monetize CDX-101, the Company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company's pre-clinical pharmaceutical candidate for macular degeneration. CDX-101 is a proprietary astaxanthin prodrug that cleaves following oral administration and delivers astaxanthin to the bloodstream. Astaxanthin is a naturally occurring molecule with safe anti-inflammatory activity that supports cardiovascular health, metabolic health, liver health, joint health, and longevity. It intends to develop zeaxanthin pharmaceutical candidate, CDX-301, for macular degeneration. Zeaxanthin accumulates in the human eye through uptake by a retinal receptor, providing protection against blue light, oxidative damage, and related inflammation that occurs in macular degeneration.
CARDAX, INC. 
